(Total Views: 601)
Posted On: 07/15/2020 12:40:26 PM
Post# of 148936
I wouldn't be disappointed if Vyera breached the commercialization agreement due to FTC and multi-state litigation associated with Daraprim.
I did the same DD and understood the intrinsic value of the royalty structure -- but I cannot think of a worse pharma company to align with from an optics point-of-view.
Lastly, since Vyera has rights to all domestic HIV indications, I have to believe that CytoDyn becomes a much more attractive [ licensing, partnership, acquisition ] target for BP if they are not in the picture.
I did the same DD and understood the intrinsic value of the royalty structure -- but I cannot think of a worse pharma company to align with from an optics point-of-view.
Lastly, since Vyera has rights to all domestic HIV indications, I have to believe that CytoDyn becomes a much more attractive [ licensing, partnership, acquisition ] target for BP if they are not in the picture.
(2)
(0)Scroll down for more posts ▼
